KRYS - Krystal Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
20.61
-0.06 (-0.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close20.67
Open20.52
Bid20.12 x 2200
Ask24.00 x 1800
Day's Range20.50 - 20.99
52 Week Range8.03 - 24.89
Volume44,501
Avg. Volume84,250
Market Cap297.38M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.25
Trade prices are not sourced from all markets
  • GlobeNewswire9 hours ago

    Krystal Biotech to Present at Evercore ISI HealthCONx

    PITTSBURGH, Nov. 20, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.

  • GlobeNewswire15 days ago

    Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Krystal Biotech (KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported financial results for the third quarter ended September 30, 2018, and provided an update on the Company’s corporate progress. It is caused by mutations in the gene coding for type VII collagen, or COL7, a major component of the anchoring fibrils, which anchor the epidermis to the underlying dermis, and provide structural adhesion in a normal individual.

  • GlobeNewswire28 days ago

    Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option

    Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has closed the previously announced underwritten public offering of 3,000,000 shares of its common stock, at a public offering price of $20.00 per share. In addition, on October 19, 2018, the underwriters fully exercised their option to purchase an additional 450,000 shares of the Company’s common stock at the public offering price, less underwriting discounts. The gross proceeds to the Company from this offering were $69.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • GuruFocus.com29 days ago

    Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $500,000 of Shares

    President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 25,000 shares of KRYS on 10/18/2018 at an average price of $20 a share.

  • PR Newswire29 days ago

    Chardan Serves as Lead Manager for Krystal Biotech

    NEW YORK , Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced that the firm is acting as lead manager in the follow-on offering for Krystal Biotech, Inc. (NASDAQ: KRYS), a gene ...

  • GlobeNewswirelast month

    Krystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock

    Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has priced the previously announced underwritten public offering of 3,000,000 shares of its common stock, at a public offering price of $20.00 per share. The Company granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock. The gross proceeds to the Company from this offering are expected to be approximately $60.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • GlobeNewswirelast month

    Krystal Biotech Announces Commencement of $60.0 Million Public Offering of Common Stock

    Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has commenced an underwritten public offering of $60.0 million of its common stock. The Company intends to grant the underwriters a 30-day option to purchase additional $9.0 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswirelast month

    Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103

    KB103 is Krystal’s first "off-the-shelf", topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa. Results on 2 patients met all primary efficacy (presence of functional COL7 expression, observation of NC1 and NC2 reactive anchoring fibrils and continued expression following repeat administration) and safety endpoints (no adverse events, inflammation or irritation) in topically administered KB103 wounds.

  • GlobeNewswire2 months ago

    Krystal Biotech to Present at Chardan Annual Genetic Medicines Conference

    PITTSBURGH, Oct. 04, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.

  • GlobeNewswire2 months ago

    Krystal Biotech to Present at 2018 Cell & Gene Meeting on the Mesa

    PITTSBURGH, Oct. 01, 2018-- Krystal Biotech Inc.,, a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Suma ...

  • GlobeNewswire2 months ago

    Krystal Biotech to Present at Upcoming Cantor Fitzgerald and Ladenburg Thalmann Conferences

    PITTSBURGH, Sept. 25, 2018-- Krystal Biotech Inc.,, a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish ...

  • GlobeNewswire3 months ago

    Krystal Biotech to Present at Upcoming B. Riley FBR and H.C. Wainwright Healthcare Investor Conferences

    PITTSBURGH, Aug. 29, 2018-- Krystal Biotech Inc.,, a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish ...

  • GlobeNewswire3 months ago

    Krystal Biotechs’ KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis

    Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (“RPDD”) to the company’s gene therapy candidate KB105, for the treatment of patients with TGM-1-deficient autosomal recessive congenital ichthyosis (“ARCI”).

  • PR Newswire3 months ago

    Chardan Capital Markets acts as Sole Placement Agent in $10 Million Securities Purchase

    NEW YORK , Aug. 17, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as sole placement agent in Krystal Biotech, Inc.'s (NASDAQ: KRYS) securities purchase agreement ...

  • Krystal Biotech (KRYS) Shares March Higher, Can It Continue?
    Zacks4 months ago

    Krystal Biotech (KRYS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).

  • Can the Rally in Krystal Biotech (KRYS) Shares Continue?
    Zacks5 months ago

    Can the Rally in Krystal Biotech (KRYS) Shares Continue?

    Krystal Biotech, Inc. (KRYS) has been on the move lately as the stock has risen by 24.5% in the past four weeks, and it is currently trading well above its 20-Day SMA

  • ACCESSWIRE6 months ago

    Blog Exposure - Krystal Biotech’s KB103 Granted Fast Track Designation by FDA for Treatment of Dystrophic Epidermolysis Bullosa

    LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Krystal Biotech, Inc. (NASDAQ: KRYS) ("Krystal"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KRYS as the Company's latest news hit the wire. On May 24, 2018, the Pennsylvania-based Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead product, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is the first-ever topically-applied herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from DEB.